Sure, here's the content translated into Chinese while keeping the HTML intact: Solana (CRYPTO:SOL)正面临看跌压力，其价格从近期高点下跌近 17%，这主要是由于 meme 币丑闻和交易量减少所致。 网络正在努力应对有关 LIBRA (CRYPTO:LIBRA)、Pumpfun 和 Meteora 等 ...

Westgold Resources (ASX:WGX) treibt Berichten zufolge Pläne voran, die Goldverarbeitungsanlage Lakewood Mill zu veräußern, die durch die 2,5 Milliarden Dollar schwere Fusion mit Karora Resources ...

Mineral Resources (ASX:MIN) has reported a decrease in revenue and a significant loss for the half-year ended Dec. 31, 2024. Revenue from ordinary activities fell by 8.9% to $2.29 billion compared to ...

Smart Parking (ASX:SPZ) has announced its expansion into the US market with the acquisition of Peak Parking, a US-based boutique parking operator. The acquisition is valued at up to US$36 million ($56 ...

Aurizon Holdings (ASX:AZJ) has announced its financial results for the first half of the fiscal year 2025, showing a slight decline in earnings before interest, tax, depreciation and amortisation ...

Australia's grainfed beef industry reached a historic milestone in 2024, with feedlots reporting record turnoffs and strong growth. According to the latest survey from the Australian Lot Feeders' ...

BHP Group (ASX:BHP), a global resources company, announced a substantial increase in profit for the half year ended Dec. 31, 2024, despite a decline in revenue. The company's profit after taxation ...

Bendigo and Adelaide Bank (ASX:BEN) reported its financial results for the half year ended Dec. 31, 2024, revealing a resilient performance despite economic challenges. Cash earnings after tax ...

Deterra Royalties (ASX:DRR) announced its financial results for the half-year ended Dec. 31, 2024. The company reported a net profit after tax of $63.9 million, a decrease of 19% compared to the same ...

Hazer Group (ASX:HZR) has completed its commercial demonstration plant and reactor test program, marking a step in the company's technological advancements. The achievement is expected to ...

Alterity Therapeutics (ASX:ATH), a biotechnology company focused on neurodegenerative diseases, announced positive results from its Phase 2 clinical trial of ATH434 for early-stage multiple system ...